Resistance in targeted cancer therapy
Nature Genetics
July 2, 2012
A therapeutic target that may prevent or overcome the acquired resistance to treatment seen in non-small cell lung cancers (NSCLC) harboring a specific gene mutation is reported this week in Nature Genetics.
Treatment of NSCLC that have a mutation in the cell surface receptor EGFR with tyrosine kinase inhibitors, such as erlotinib, extends life by an average of about three months. However, with this treatment, tumors almost always acquire resistance.
Trever Bivona and colleagues show that the enzyme AXL kinase is upregulated in some resistant human NSCLC. They further showed that inhibiting AXL function in cell and mouse models of resistant tumors restored sensitivity to the common NSCLC drug erlotinib. The authors suggest AXL as a therapeutic target that for patients with acquired resistance in EGFR-mutant lung cancer.
doi: 10.1038/ng.2330
Research highlights
-
Jun 29
COVID-19: Assessing instances of long COVID in UK health dataNature Communications
-
Jun 24
Palaeontology: It sucked to be the prey of ancient cephalopodsScientific Reports
-
Jun 24
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
Jun 23
Scientific community: Women credited less than men in scientific paper authorshipNature
-
Jun 17
Health technology: New cost-effective smartphone test for middle ear functionCommunications Medicine
-
Jun 17
Conservation: Feral cats pushing critically endangered marsupial further towards extinctionScientific Reports